The Plenipotentiary Representative of the President of the Russian Federation in the Volga Federal District Igor Komarov was informed about import substitution projects of Promomed Group

Promomed 24 November 2023

On November 21, the Plenipotentiary Representative of the President of the Russian Federation in the Volga Federal District Igor Komarov visited the Biokhimik plant of Promomed Group. Alexander Efremov, General Director of PROMOMED DM LLC, and Alexey Klyuchnikov, Production Director of Biokhimik JSC, demonstrated a high-tech production line for tablets and capsules, and talked about the Company's import-substituting projects.

Biokhimik plant, the production site of Promomed Group, continues deep modernization and significant renewal of the product portfolio with a focus on high-tech and intellectually rich products. In 2023, the Company's portfolio was replenished with the three hundredth drug; about 100 more are in development, including 40 molecules which mass production will be launched in 2023. Most of the new molecules are vital drugs used in the treatment of cancer, infectious hepatitis, HIV, endocrinological and neurological diseases.

The company actively participates in the import substitution program. The advanced research base of Promomed challenges foreign products and supports urgent measures to substitute foreign manufacturers leaving the market. For example, at the end of 2022, Novo Nordisk (Denmark) announced the cessation of supplies of vital medicines for the treatment of diabetic patients and overweight patients, in March 2023 shipments have been stopped. Promomed Group and Biokhimik accepted the challenge, developed the necessary drug and a pen injector for it. Nine months later, in cooperation with the Medsintez plant, Enligria and Quincenta have been launched and completely replaced the products of a pharmaceutical manufacturer from unfriendly country.

Biokhimik continues to introduce modern approaches to improve labor productivity. In 2023, a semi–automatic line for the production of tablets and capsules reached full speed – the only one in the country and one of three in Europe. Igor Komarov examined with interest the latest equipment in operation. He made a special mention that the capacity of the new line of up to 1 billion tablets and capsules per year is really impressive and demonstrates real import substitution in the pharmaceutical industry in the country.

This is the second visit of Igor Komarov to the Biokhimik plant. In April 2021, he visited the workshop for the production of pharmaceutical substances for antibiotics and finished medicines in ampoules. At that time, the main purpose of the visit was the contribution of the pharmaceutical industry to the measures against the coronavirus pandemic.